Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
- Published In:
- Journal for immunotherapy of cancer, 12(5) (2024)
- Authors:
- Mørk, Sofie Kirial, Skadborg, Signe Koggersbøl, Albieri, Benedetta, Draghi, Arianna, Bol, Kalijn, Kadivar, Mohammad, Westergaard, Marie Christine Wulff, Stoltenborg Granhøj, Joachim, Borch, Annie, Petersen, Nadia Viborg, Thuesen, Nikolas, Rasmussen, Ida Svahn, Andreasen, Lars Vibe, Dohn, Rebecca Bach, Yde, Christina Westmose, Noergaard, Nis, Lorentzen, Torben, Soerensen, Anders Bundgaard, Kleine-Kohlbrecher, Daniela, Jespersen, Anders, Christensen, Dennis, Kringelum, Jens, Donia, Marco, Hadrup, Sine Reker, Marie Svane, Inge
- Database ID:
- RPEP-08919
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08919APA
Mørk, Sofie Kirial; Skadborg, Signe Koggersbøl; Albieri, Benedetta; Draghi, Arianna; Bol, Kalijn; Kadivar, Mohammad; Westergaard, Marie Christine Wulff; Stoltenborg Granhøj, Joachim; Borch, Annie; Petersen, Nadia Viborg; Thuesen, Nikolas; Rasmussen, Ida Svahn; Andreasen, Lars Vibe; Dohn, Rebecca Bach; Yde, Christina Westmose; Noergaard, Nis; Lorentzen, Torben; Soerensen, Anders Bundgaard; Kleine-Kohlbrecher, Daniela; Jespersen, Anders; Christensen, Dennis; Kringelum, Jens; Donia, Marco; Hadrup, Sine Reker; Marie Svane, Inge. (2024). Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.. Journal for immunotherapy of cancer, 12(5). https://doi.org/10.1136/jitc-2024-008817
MLA
Mørk, Sofie Kirial, et al. "Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.." Journal for immunotherapy of cancer, 2024. https://doi.org/10.1136/jitc-2024-008817
RethinkPeptides
RethinkPeptides Research Database. "Dose escalation study of a personalized peptide-based neoant..." RPEP-08919. Retrieved from https://rethinkpeptides.com/research/mork-2024-dose-escalation-study-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.